Skip to content

CKD Management & Progression Slowing

Slowing the loss of kidney function through blood pressure control, SGLT2 inhibitor therapy, and management of the anemia, bone disease, and acidosis that come with it — at Remix Medical in Houston, TX.

Chronic kidney disease is not one thing that happens to you. It is a rate — how fast function is being lost. Almost everything we do is aimed at slowing that rate.

What actually changes the trajectory

Most of what protects a kidney is unglamorous and enormously effective.

Blood pressure. The single largest modifiable factor. Target is generally under 120 systolic when tolerated, and getting there often takes three or four medications.

SGLT2 inhibitors. The most significant advance in kidney medicine in thirty years. Dapagliflozin and empagliflozin slow progression substantially, in patients with and without diabetes. If you have chronic kidney disease (CKD) with protein in the urine, you should be on one unless there is a reason you cannot be.

ACE inhibitors or ARBs. They reduce proteinuria and protect the kidney beyond their effect on blood pressure. A modest rise in creatinine after starting one is expected and is not a reason to stop.

Finerenone. For diabetic kidney disease, added on top of the above.

Glucose control, if you are diabetic.

Stopping the drugs that are hurting you. NSAIDs, certain antibiotics, contrast studies ordered without thought. A large fraction of preventable kidney injury comes from medications.

What we manage alongside it

CKD does not fail alone. Each of these is treated as its own problem, on its own schedule.

  • Anemia — the kidney stops making erythropoietin
  • Bone and mineral disease — phosphorus rises, calcium falls, parathyroid hormone climbs
  • Metabolic acidosis — corrected with bicarbonate, which itself slows progression
  • Potassium — which often constrains the very medications that protect the kidney
  • Cardiovascular risk — far more CKD patients die of heart disease than reach dialysis

Advanced planning

When your eGFR falls below 30, we start talking about what comes next — not because it is imminent, but because the patients who do well are the ones who had time to choose.

Below 20, you can be evaluated for transplant and listed before dialysis ever begins. If you will need dialysis, a fistula takes three to six months to mature. Rushing these decisions is how people end up with a catheter in their neck in an emergency room.

What we track

At each visit: eGFR, urine albumin-to-creatinine ratio, potassium, bicarbonate, hemoglobin, phosphorus, calcium, and parathyroid hormone. The interval depends on your stage and how fast you are moving.

The slope of your eGFR over time tells us more than any single value. A patient at 35 who has been stable for six years and a patient at 35 who was at 55 last year are in entirely different situations.

How it's performed

Management centers on reducing the rate of eGFR decline. Blood pressure is titrated to target, typically below 120 systolic when tolerated. SGLT2 inhibitor therapy is initiated in patients with albuminuria regardless of diabetes status. Renin-angiotensin system blockade with an ACE inhibitor or ARB is maximized to reduce proteinuria. Finerenone is added in diabetic kidney disease. Nephrotoxic agents are identified and discontinued. Complications are treated in parallel: anemia, mineral and bone disorder, metabolic acidosis, hyperkalemia, and cardiovascular risk. Laboratory surveillance at each visit tracks eGFR, albumin-to-creatinine ratio, potassium, bicarbonate, hemoglobin, phosphorus, calcium, and parathyroid hormone. Below an eGFR of 30, planning for kidney replacement therapy begins; below 20, preemptive transplant evaluation is initiated.

How to prepare

Bring every medication you take, including over-the-counter drugs, supplements, and herbal products, to each visit. Many are nephrotoxic. If you monitor your blood pressure at home, bring the readings. Laboratory work is typically drawn before the visit so results can be reviewed together.

Outcome

A measurable reduction in the rate of eGFR decline. SGLT2 inhibitor therapy and renin-angiotensin blockade together substantially delay progression to kidney failure. Parallel management of anemia, mineral and bone disorder, and acidosis reduces morbidity, while early planning for transplant or dialysis produces markedly better outcomes than urgent, unplanned initiation.

Ready to see a nephrologist in Houston?

Book your first visit, or call us to verify your insurance and ask any questions about nephrology care.

Your physician

Your nephrology at Remix Medical.

Every clinician at Remix Medical is board-certified and owns the practice — so the physician in your exam room is the one making decisions about your care.

  • Uday Khosla, MD

    Nephrologist

    Montrose — Upper Kirby · Limestone County — Groesbeck · Katy — Grand Parkway · East Houston — Woodforest

    Board certifiedAccepting newBook
Specialty
Nephrology & Hypertension
Type
Therapy
CPT code
99213, 99214, 99215 (established patient E/M, moderate to high complexity); G0556, G0557, G0558 (Advanced Primary Care Management); 99490, 99439 (chronic care management); 99487, 99489 (complex chronic care management)

Also known as: Chronic Kidney Disease Management, CKD Care, Kidney Disease Progression Slowing, Renal Protection, Nephroprotection, CKD Treatment

This page is for general education and is not a substitute for medical advice. Whether a given procedure is appropriate depends on your individual evaluation. Contact a Remix Medical clinician to discuss your care.

Updated July 9, 2026.

Ready to see a specialist?